Exploring Thyroid Cancer & Autoimmune Thyroiditis: Study Insights with Dr. De Leo

Published 2024-05-31
We are honored to have Dr. Simone De Leo present "A Prospective Multicenter Study Examining the Relationship Between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis." Dr. Haixia Guan joins as the featured expert discussant.

0:00 Webinar

3:32 Dr. De Leo presents

5:00 Dr. De Leo Introduces HT & PTC Relationship
Hashimoto’s thyroiditis (HT) and thyroid cancer often occur together, with reports of coexistence ranging from 10–60% in the literature. Papillary thyroid carcinoma (PTC) is most commonly associated with HT. Studies show that HT lowers the chance of central and lateral lymph node metastasis, ETE, and vascular invasion. PTC associated with HT is at a lower stage and lower risk.

10:00 Dr. De Leo Presents the Study
Dr. De Leo conducted a prospective study using data from patients in the Italian Thyroid Cancer Observatory (n=4233). Nearly a third had associated thyroiditis. Results show that patients with thyroiditis were younger with smaller tumors and lower risk but were more likely to have a biochemically incomplete or indeterminate response due to the difficulty of achieving complete surgical thyroid removal.

28:00 Dr. Guan Discusses HT & PTC Implications
Individuals with HT have better outcomes and less aggressive PTC characteristics, suggesting a protective effect of autoimmune thyroiditis on thyroid cancer. This may be due to greater lymphocyte infiltration. Although HT is associated with thyroid cancer, its role in causing PTC is controversial. HT may restrict thyroid cancer progression and is linked to a better prognosis.

41:13 Discussion with Q&A

** Check out our other programs! **

The THANC Guide
thancguide.org/

TIRO: Thyroid Int'l Recommendations Online
tiro.expert/

** Follow us on Twitter! **
@thancfoundation - shorturl.at/puwS0

THANC on FB - shorturl.at/svNY4

All Comments (1)